Albemarle Corporation (NYSE:ALB) Receives Consensus Rating of "Hold" from Analysts

Shares of Albemarle Corporation (NYSE:ALB - Get Free Report) have been assigned an average rating of "Hold" from the twenty-one brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $91.62.

ALB has been the topic of a number of research reports. UBS Group decreased their price target on Albemarle from $86.00 to $64.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Mizuho cut their target price on shares of Albemarle from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Friday, March 7th. JPMorgan Chase & Co. reduced their price objective on shares of Albemarle from $80.00 to $60.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Wells Fargo & Company cut their target price on Albemarle from $80.00 to $60.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Finally, Morgan Stanley dropped their price target on shares of Albemarle from $68.00 to $58.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th.

Albemarle Stock Performance

NYSE ALB opened at $59.82 on Wednesday. The company has a current ratio of 2.11, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. Albemarle has a twelve month low of $49.43 and a twelve month high of $113.91. The stock has a 50-day moving average of $58.25 and a 200 day moving average of $74.80. The stock has a market capitalization of $7.04 billion, a price-to-earnings ratio of -5.38 and a beta of 1.61.

Albemarle (NYSE:ALB - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The specialty chemicals company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.44. The firm had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.18 billion. Albemarle had a negative net margin of 22.39% and a negative return on equity of 1.92%. The firm's revenue for the quarter was down 20.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 EPS. Sell-side analysts anticipate that Albemarle will post -0.04 EPS for the current fiscal year.

Albemarle Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 1st. Shareholders of record on Friday, June 13th will be given a $0.405 dividend. This represents a $1.62 annualized dividend and a yield of 2.71%. The ex-dividend date is Friday, June 13th. Albemarle's dividend payout ratio (DPR) is presently -14.57%.

Institutional Trading of Albemarle

A number of hedge funds have recently made changes to their positions in the company. O Shaughnessy Asset Management LLC acquired a new stake in Albemarle in the fourth quarter valued at $218,000. Renaissance Technologies LLC boosted its position in Albemarle by 2,151.9% during the 4th quarter. Renaissance Technologies LLC now owns 60,800 shares of the specialty chemicals company's stock valued at $5,234,000 after purchasing an additional 58,100 shares during the period. Atria Investments Inc increased its position in Albemarle by 6.9% in the fourth quarter. Atria Investments Inc now owns 5,575 shares of the specialty chemicals company's stock worth $480,000 after buying an additional 359 shares during the period. GAMMA Investing LLC lifted its stake in Albemarle by 6,393.1% in the first quarter. GAMMA Investing LLC now owns 152,394 shares of the specialty chemicals company's stock valued at $10,975,000 after buying an additional 150,047 shares during the last quarter. Finally, Himension Capital Singapore PTE. LTD. raised its holdings in shares of Albemarle by 50.7% during the fourth quarter. Himension Capital Singapore PTE. LTD. now owns 220,834 shares of the specialty chemicals company's stock valued at $19,009,000 after buying an additional 74,322 shares during the last quarter. Hedge funds and other institutional investors own 92.87% of the company's stock.

Albemarle Company Profile

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.